Categories: News

Tsingke Gene Leads a Delivery Revolution with “Calendar Day Delivery”

BEIJING, April 23, 2025 /PRNewswire/ — In March 2025, Tsingke pioneered the industry’s first full-range “Calendar Day Delivery” model, redefining standards for gene synthesis services through a comprehensive suite of offerings such as Tsynth™Gene Synthesis, PCR Cloning & Subcloning, Site-directed Mutagenesis, Plasmid Preparation, and more, tailored to diverse research needs.

As the first gene synthesis company to publicly commit to “calendar day fulfillment,” this service model ensures that delivery time is calculated based on calendar days, uninterrupted by weekends or holidays. This breakthrough eliminates the long-standing bottleneck of holiday delays, shortening the overall delivery cycle by 1 to 13 days, with the fastest delivery in just 3 days, setting a new industry benchmark.

Five Core Technological Pillars Behind Calendar Day Delivery

1. Fully Self-Controlled Industrial Chain: Complete independence in synthesis materials, equipment, and processes.

2. Reduced Primer Synthesis Mutation Rate: Minimizing rework by improving initial synthesis accuracy.

3. Enhanced Gene Assembly Efficiency: Increased capability for multi-fragment synthesis.

4. Upgraded Detection Technology: Dual assurance with Sanger sequencing and NGS.

5. Smart Production System: MES system management with meticulous control at every step.

According to Tsingke Gene Synthesis Director, “Calendar Day Delivery is not just about changing the numbers in turnaround time, it’s a redefinition of our R&D and production efficiency. Through a fully self-sufficient industrial chain in gene synthesis, we are helping scientists worldwide dedicate more time to innovation itself.”

Gene Factory Builds an Efficient Delivery System

Tsingke Gene Factory adopts a smart, factory-based approach, integrating synthesis materials, equipment, and processes to construct intelligent synthesis pipelines. Empowered by a digital management system, the factory provides a comprehensive range of products and services—centered on gene synthesis—including oligo synthesis/modification, gene detection, chemical reagents, biological reagents, laboratory instruments, protein&antibody, gene regulation, and more. This creates robust delivery capabilities and synergistic product advantages.

Summary and Outlook

In today’s increasingly complex global supply chain environment, Tsingke’s “Calendar Day Delivery” not only represents an upgrade in service models but also highlights the power of independent innovation in China’s biotechnology sector. As the “Tsingke Gene Factory” model continues to deepen, Tsingke will further optimize its industrial chain integration to ensure both speed and quality in delivery, accelerate the implementation of cutting-edge technologies, and provide more efficient and reliable support for scientists around the world.

For more information on Tsingke, please visit https://www.tsingke.com/ or connect with us on LinkedIn at https://www.linkedin.com/company/tsingke/.

Beijing Tsingke Biotech Co., Ltd.

market@tsingke.com.cn

View original content to download multimedia:https://www.prnewswire.com/news-releases/tsingke-gene-leads-a-delivery-revolution-with-calendar-day-delivery-302435677.html

SOURCE Tsingke Biotech

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

1 hour ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

4 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

4 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

4 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

4 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

4 hours ago